Last month, the U.S. Food and Drug Administration (the “FDA”) announced in a Declaratory Order the resolution of the shortage of semaglutide ...

A coalition of over 20 leading health organizations is calling on the U.S. Food & Drug Administration (FDA) to enforce federal regulations on compounded we ...

Copycat versions of Eli Lilly’s diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They’re ...

Fact checked by Nick Blackmer “Microdosing” GLP-1 drugs like Ozempic is gaining attention on social media, but doctors say it ...

Drug compounders are moving to block the FDA’s decision that Novo Nordisk A/S’s weight loss drug is no longer in shortage, ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

The FBI has issued a warning about counterfeit versions of compounded weight loss drugs, which have been found to contain "unknown drugs, hig ...

Hims & Hers Health, Inc. stock faces volatility after an FDA halt on its GLP-1 drug. Click here to find out why HIMS stock is ...

GLP-1 agonists remain out of reach for many due to high costs, leading some patients to turn to unsafe compounded versions ...

Study Links Ozempic to Hair Loss in Women There have been ongoing discussions online about a potential link between Ozempic and hair loss, akin to other alleged side effects of the medication such as ...

A new study links semaglutide, the active ingredient in Ozempic and Wegovy, to a higher risk of hair loss, especially in ...

For years, people taking GLP-1 type drugs (e.g., Ozempic, Wegovy) have noticed that the medicines didn’t just help them to ...